drugset / Trial / NCT02973516

Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis

NCT02973516

Phase 2 Completed 41 enrolled Guerbet
NaSingle-groupOpen-labelDiagnostic

Summary

This study is an exploratory study aiming to collect data about diagnosis efficacy (sensitivity and specificity) of P03277 triphasic liver imaging for HCC in subjects with suspected small nodules and chronic liver disease. 30 subjects will be included, having HCC confirmed or not by previous enhanced CT and/or MRI and before any biopsy for histology analysis. The standard of reference for diagnosis will be given by the site according to their standard of care and adapted from EASL/EORTC diagnostic criteria (considering previous contrast enhanced imaging (CT and/or MRI) and/or biopsy specimen analysis given on-site and/or the more recent AFP results available). 10 additional subjects will be included to explore the diagnostic efficacy for HCC at half dose of P03277.

Timeline

Start
2016-12
Primary completion
2019-04-04
Completion
2019-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Gadopiclenol Diagnostic / imaging agent 0.05 mmol Intravenous
Subject Gadopiclenol Diagnostic / imaging agent 0.1 mmol Intravenous